Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Common Equity (2016 - 2025)

Historic Common Equity for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $2.8 million.

  • Alaunos Therapeutics' Common Equity rose 290.01% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 290.01%. This contributed to the annual value of $2.1 million for FY2024, which is 6670.37% down from last year.
  • Alaunos Therapeutics' Common Equity amounted to $2.8 million in Q3 2025, which was up 290.01% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Alaunos Therapeutics' Common Equity ranged from a high of $105.6 million in Q1 2021 and a low of $1.1 million during Q1 2025
  • Over the past 5 years, Alaunos Therapeutics' median Common Equity value was $21.6 million (recorded in 2023), while the average stood at $30.2 million.
  • As far as peak fluctuations go, Alaunos Therapeutics' Common Equity crashed by 8374.39% in 2024, and later skyrocketed by 290.01% in 2025.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' Common Equity stood at $58.1 million in 2021, then crashed by 33.59% to $38.6 million in 2022, then tumbled by 83.64% to $6.3 million in 2023, then tumbled by 66.7% to $2.1 million in 2024, then soared by 33.48% to $2.8 million in 2025.
  • Its Common Equity was $2.8 million in Q3 2025, compared to $3.7 million in Q2 2025 and $1.1 million in Q1 2025.